Sepsis- The Dilemma Continues

Guimei, Maha

doi:10.15406/moji.2016.04.00125

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon entry of microbial particles into the respiratory mucosa and infection of lung resident cells, a series of immune reactions take place corroborated with a cytokine storm within the body, resulting in the impairment of the coagulation system, and the generation of disseminated intravascular coagulation leading to septic shock and multi-organ disorder. 56 Lymphopenia has been reported to be associated with COVID-19 infection, indicating that SARS-CoV-2 destroys numerous immune cells and hinders the cellular immune responses. This suggests that SARS-CoV-2 might primarily act on monocytes and T cells, similar to the previously reported SARS-CoV.…”

Section: Status Of Nk Cells During Covid-19 Infectionmentioning

confidence: 99%

<p>Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?</p>

Al‐Ani¹,

Elemam²,

Hundt³

et al. 2020

IDR

View full text Add to dashboard Cite

COVID-19 infection caused by the newly discovered coronavirus severe acute respiratory distress syndrome virus-19 (SARS-CoV-2) has become a pandemic issue across the globe. There are currently many investigations taking place to look for specific, safe and potent anti-viral agents. Upon transmission and entry into the human body, SARS-CoV-2 triggers multiple immune players to be involved in the fight against the viral infection. Amongst these immune cells are NK cells that possess robust antiviral activity, and which do not require prior sensitization. However, NK cell count and activity were found to be impaired in COVID-19 patients and hence, could become a potential therapeutic target for COVID-19. Several drugs, including glatiramer acetate (GA), vitamin D 3 , dimethyl fumarate (DMF), monomethyl fumarate (MMF), natalizumab, ocrelizumab, and IFN-β, among others have been previously described to increase the biological activities of NK cells especially their cytolytic potential as reported by upregulation of CD107a, and the release of perforin and granzymes. In this review, we propose that such drugs could potentially restore NK cell activity allowing individuals to be more protective against COVID-19 infection and its complications.

show abstract

Section: Status Of Nk Cells During Covid-19 Infectionmentioning

confidence: 99%